Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

40.06 +0.76 (+1.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TG Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022
Upgrades 
Via Benzinga
What 4 Analyst Ratings Have To Say About TG Therapeutics
Over the past 3 months, 4 analysts have published their opinion on TG Therapeutics (NASDAQ:TGTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity. 
Via Benzinga
Expert Ratings for TG Therapeutics
TG Therapeutics (NASDAQ:TGTX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Despite Price Cut, HC Wainwright Keeps Buy Rating On TG Therapeutics - Read Why
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! It's time to start off another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
68 Biggest Movers From Yesterday
Gainers Casa Systems, Inc. (NASDAQ: CASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core... 
Via Benzinga
TG Therapeutics Retracts FDA Request For Ublituximab / Ukoniq Combo In Blood Cancers
Via Benzinga
TG Therapeutics: Q4 Earnings Insights
TG Therapeutics (NASDAQ:TGTX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Mid-Afternoon Market Update: Crude Oil Rises Over 1%; Nektar Therapeutics Shares Slide
U.S. stocks traded higher in volatile session, with the Dow Jones gaining around 60 points toward the end of trading on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Natus Medical (NASDAQ:NTUS) shares rose 28.8% to $33.55 during Monday's regular session. The current volume of 3.0 million shares is 2073.2% of Natus Medical... 
Via Benzinga
Mid-Day Market Update: U.S. Stocks Turn Lower; Bank of America Earnings Top Views
U.S. stocks turned lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday. 
Via Benzinga
34 Stocks Moving In Monday's Mid-Day Session
Gainers Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions.... 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; Dow Gains 100 Points
U.S. stocks traded higher this morning, with the Dow Jones adding around 100 points on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Natus Medical (NASDAQ:NTUS) stock rose 28.3% to $33.42 during Monday's pre-market session. The market value of their outstanding shares is at $1.1 billion.... 
Via Benzinga
Why TG Therapeutics Stock Is Plunging Today
TG Therapeutics Inc (NASDAQ: TGTX) shares are trading significantly lower Monday morning after the company announced it has voluntarily withdrawn the pending Biologics... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Raymond James cut The Estée Lauder Companies Inc. (NYSE: EL) price target from $390 to $345. Estée Lauder shares rose 0.4% to $264.95 in pre-market trading. 
Via Benzinga
21 Stocks Moving in Monday's Pre-Market Session
Gainers Mullen Automotive, Inc. (NASDAQ: MULN) shares rose 16.2% to $2.51 in pre-market trading. Mullen Automotive announced plans to begin construction for EV battery pack... 
Via Benzinga
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with... 
Via Benzinga
TG Therapeutics, Inc. (NASDAQ:TGTX) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 03/23/2022 -- Certain directors of TG Therapeutics, Inc are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Looking Into TG Therapeutics's Return On Capital Employed
TG Therapeutics (NASDAQ:TGTX) brought in sales totaling $2.32 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 8.99%, resulting in a loss... 
Via Benzinga
FDA Pushes TG Therapeutics' Ublituximab / Ukoniq Combo Therapy Applications In Blood Cancer Settings
The FDA has extended the review period of TG Therapeutics Inc's (NASDAQ: TGTX) biologics license application and supplemental New Drug Application for... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by... 
Via Benzinga
Global Multiple Sclerosis Drugs Market Expected to Reach $41.99 Billion in 2028
Palm Beach, FL –– February 3, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system. It is characterized by demyelination,... 
Via FinancialNewsMedia
Exposures COVID-19
Massive Month-End Buying of Biggest Losers
The average stock in the Russell 3,000 is now up 7% from the index’s low point last Friday as we near the final close of January 2022. 
Via Talk Markets
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.